UK telehealth data show semaglutide switching jumped after tirzepatide price rise

The wire

1. 01A retrospective cohort in Diabetes, Obesity & Metabolism covering 1,033,522 UK adults found 90.2% started tirzepatide and 9.8% semaglutide, with switching to semaglutide up 9.26 percentage points after the up-to-170% tirzepatide list-price increase.
2. 02The data quantify how sharply self-paying patients respond to price in a telehealth channel, a direct read for operators setting formulary and pricing strategy.
3. 03Estimated 12-month weight loss was 19.93% with tirzepatide (n=30,763) versus 16.40% with semaglutide (n=979); the semaglutide follow-up group is small and the study is observational from a single provider.

From the source

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity

Diabetes, obesity & metabolism · 2026 Oct 14 · Dix S, Mulligan A, Ficarelli M et al.